← Eichor
Study identifier: NCT07655115 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th

Condition: Autism Spectrum Disorders  ·  Sponsor: Hospital General Universitario Gregorio Marañon

PhasePhase 3
Planned participants103
Who can joinAll sexes, 0 Years to 64 Years
Healthy volunteersNo

About this study

study with arbaclofen (4 weeks of titration and then 6 weeks of active/stable treatment). The effects of arbaclofen on target EEG and ERG metrics will be associated with the clinical response in measures of social and general function, adaptive behaviour, social anxiety, sensory behaviours, global functioning, and quality of life in Children and Adolescents with Autism Spectrum Disorders

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (5)

Assistance Publique Hopitaux De ParisParis, FranceRecruiting
Hospital Clinic De BarcelonaBarcelona, SpainRecruiting
Hospital General Universitario Gregorio MarañónMadrid, SpainRecruiting
Hospital Universitario De SalamancaSalamanca, SpainRecruiting
Complejo Asistencial De Zamora Hospital Provincial De ZamoraZamora, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07655115